These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22388760)

  • 41. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
    Stahl P; Seeschaaf C; Lebok P; Kutup A; Bockhorn M; Izbicki JR; Bokemeyer C; Simon R; Sauter G; Marx AH
    BMC Gastroenterol; 2015 Feb; 15():7. PubMed ID: 25649416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 gene amplification in patients with breast cancer with equivocal IHC results.
    Meijer SL; Wesseling J; Smit VT; Nederlof PM; Hooijer GK; Ruijter H; Arends JW; Kliffen M; van Gorp JM; Sterk L; van de Vijver MJ
    J Clin Pathol; 2011 Dec; 64(12):1069-72. PubMed ID: 21836036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
    Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z
    Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.
    Sharif S; Ramanathan RK; Potter D; Cieply K; Krasinskas AM
    Dig Dis Sci; 2008 Nov; 53(11):3026-32. PubMed ID: 18463983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
    Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR gene and protein expression in breast cancers.
    Park K; Han S; Shin E; Kim HJ; Kim JY
    Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
    Loring P; Cummins R; O'Grady A; Kay EW
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):194-200. PubMed ID: 15894935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival.
    López-Guerrero JA; Llombart-Cussac A; Noguera R; Navarro S; Pellin A; Almenar S; Vazquez-Alvadalejo C; Llombart-Bosch A
    Int J Cancer; 2006 Apr; 118(7):1743-9. PubMed ID: 16217770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
    Fusco N; Rocco EG; Del Conte C; Pellegrini C; Bulfamante G; Di Nuovo F; Romagnoli S; Bosari S
    Mod Pathol; 2013 Jun; 26(6):816-24. PubMed ID: 23348899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
    Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
    Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks.
    Bethune GC; Mullen JB; Chang MC
    Ann Diagn Pathol; 2015 Dec; 19(6):385-90. PubMed ID: 26372078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.
    Oikawa M; Yoshiura K; Kondo H; Miura S; Nagayasu T; Nakashima M
    Radiat Oncol; 2011 Dec; 6():168. PubMed ID: 22152285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases.
    Chang MC; Malowany JI; Mazurkiewicz J; Wood M
    Mod Pathol; 2012 May; 25(5):683-8. PubMed ID: 22282306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V; Voutsadakis IA
    Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
    [No Abstract]   [Full Text] [Related]  

  • 60. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
    Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
    Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.